pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News mentioning Immunology
280
stories
17d
Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
biospace
17d
Coveted metabolic gem Rhythm reportedly gets $10B offer from AstraZeneca
biospace
17d
Evommune signs $1B deal with China’s Hinova to enter same molecular glue niche as Novartis
fiercebiotech
17d
Sanofi stops development of Nurix-partnered immune drug
biopharma dive
17d
AbbVie bets up to $1.47B for Nxera’s discarded IBD program
biospace
17d
Sanofi ends development of Nurix's STAT6 degrader
endpoints
17d
Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’
biospace
18d
Sanofi scraps STAT6 degrader from Nurix just 2 months after entering clinic
fiercebiotech
18d
T-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
fiercebiotech
19d
Pfizer flat in Q3 despite 32% growth for new and acquired products
biospace
19d
AbbVie invests £120M in UK, including expanded R&D site
fiercebiotech
19d
STAT+: Pharmalittle: We’re reading about payments to Russian middlemen, a possible Dupixent rival, and more
stat
20d
STAT+: Coming readout of Kymera eczema trial is a high-stakes moment in a bid to rival Dupixent
stat
22d
AbbVie’s Q3 beat should keep ‘train rolling’ as company eyes bolt-on deals
biospace
22d
AstraZeneca employs $1.5B cost savings to reinvest back into growth
biospace
22d
Regeneron achieves ‘clean sweep’ in Q3 with myriad pipeline catalysts on deck
biospace
22d
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
biospace
23d
Opinion: How Congress can fix expert advisory committees
stat
23d
Aspen Neuroscience lands $141M IPO, while Bambusa secures $169M
endpoints
23d
Sanofi considering ‘moonshot’ treatments as M&A targets to survive Dupixent patent cliff
fiercebiotech
23d
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
biospace
23d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
23d
Chutes & Ladders—Lilly unifies global markets as 36-year vet Patrik Jonsson retires
fiercebiotech
24d
STAT+: Vertex kidney disease drug scrutinized for infection risk
stat
24d
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
24d
Flagship brings 3 biotech platforms together to launch AI drug discovery player Etcelera
fiercebiotech
24d
STAT+: Senate candidate El-Sayed wants to ‘grill’ RFK Jr., calls him the ‘most incompetent HHS secretary ever’
stat
25d
Biogen CEO tells analysts he’s focused on early-stage R&D as ‘we were not very good with that’
fiercebiotech
25d
Big Pharma is ready to strike, with J&J most likely to buy: Leerink
biospace
26d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
← prev
page 2 of 10
next →